» Articles » PMID: 34175786

Primary Care Physicians' Preparedness to Treat Opioid Use Disorder in the United States: A Cross-sectional Survey

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2021 Jun 27
PMID 34175786
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Efforts to increase opioid use disorder (OUD) treatment have focused on primary care. We assessed primary care physicians' preparedness to identify and treat individuals with OUD and barriers to increasing buprenorphine prescribing.

Methods: We conducted a cross-sectional survey from January-August 2020 which assessed perceptions of the opioid epidemic; comfort screening, diagnosing, and treating individuals with OUD with medications; and barriers to obtaining a buprenorphine waiver and prescribing buprenorphine in their practice. Primary care physicians were sampled from the American Medical Association Physician Master File (n = 1000) and contacted up to 3 times, twice by mail and once by e-mail.

Results: Overall, 173 physicians (adjusted response rate 27.3 %) responded. While most were somewhat or very comfortable screening (80.7 %) and diagnosing (79.3 %) OUD, fewer (36.9 %) were somewhat or very comfortable treating OUD with medications. One third of respondents were in a practice where they or a colleague were waivered and 10.7 % of respondents had a buprenorphine waiver. The most commonly cited barriers to both obtaining a waiver and prescribing buprenorphine included lack of access to addiction, behavioral health, or psychiatric co-management, lack of experience treating OUD, preference not to be inundated with requests for buprenorphine, and the buprenorphine training requirement.

Conclusions: While most primary care physicians reported comfort screening and diagnosing OUD, fewer were comfortable treating OUD with medications such as buprenorphine and even fewer were waivered to do so. Addressing provider self-efficacy and willingness, and identifying effective, coordinated, and comprehensive models of care may increase OUD treatment with buprenorphine.

Citing Articles

Physician Reluctance to Intervene in Addiction: A Systematic Review.

Campopiano von Klimo M, Nolan L, Corbin M, Farinelli L, Pytell J, Simon C JAMA Netw Open. 2024; 7(7):e2420837.

PMID: 39018077 PMC: 11255913. DOI: 10.1001/jamanetworkopen.2024.20837.


Treatment for Opioid Use Disorder: Population Estimates - United States, 2022.

Dowell D, Brown S, Gyawali S, Hoenig J, Ko J, Mikosz C MMWR Morb Mortal Wkly Rep. 2024; 73(25):567-574.

PMID: 38935567 PMC: 11254342. DOI: 10.15585/mmwr.mm7325a1.


Preparing Medical Students to Care for Patients with Opioid Use Disorder: Buprenorphine Waiver Training in Undergraduate Medical Education.

Riser E, Kennedy A, Holterman L, Brooklyn J, Maruti S, Sobel H Acad Psychiatry. 2024; 48(3):263-267.

PMID: 38684575 DOI: 10.1007/s40596-024-01968-w.


Therapeutic Potential of Buprenorphine in Depression: A Meta-Analysis of Current Evidence.

Bhivandkar S, Sarfraz Z, Jain L, Bachu A, Malo P, Hsu M J Clin Med Res. 2024; 16(2-3):46-55.

PMID: 38550549 PMC: 10970042. DOI: 10.14740/jocmr5050.


Internal Medicine Resident Addiction Training at the Veteran's Health Administration: A Qualitative Evaluation of Site Directors' Response to the 2022 ACGME Requirements.

Richardson C, Daniels K, Confer A, Saxon A, Gordon A, Liberto J J Gen Intern Med. 2024; 39(8):1393-1399.

PMID: 38302815 PMC: 11169109. DOI: 10.1007/s11606-024-08639-4.


References
1.
Jones C, McCance-Katz E . Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2018; 114(3):471-482. DOI: 10.1111/add.14436. View

2.
Saloner B, Stoller K, Alexander G . Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment. N Engl J Med. 2018; 379(1):4-6. PMC: 6522243. DOI: 10.1056/NEJMp1804059. View

3.
Cunningham C, Kunins H, Roose R, Elam R, Sohler N . Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007; 22(9):1325-9. PMC: 2219773. DOI: 10.1007/s11606-007-0264-7. View

4.
Jones C, Campopiano M, Baldwin G, McCance-Katz E . National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015; 105(8):e55-63. PMC: 4504312. DOI: 10.2105/AJPH.2015.302664. View

5.
Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G . Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020; 17(1):26. PMC: 7201394. DOI: 10.1186/s12954-020-00370-7. View